Recently Published European Consensus Guidelines Highlight the Need for a Bedside Test. LONDON--(BUSINESS WIRE)--SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, announced data validating the efficacy of a lung maturity test (LMT) in identifying infants at risk of respiratory distress syndrome (RDS) who could benefit from early surfactant treatment.